论文信息 - First-in-human clinical trial results with ABBV-184, a first-in-class T-cell Receptor/Anti-CD3 bispecific protein, in adults with Previously treated AML or NSCLC. - 字舞流文

First-in-human clinical trial results with ABBV-184, a first-in-class T-cell Receptor/Anti-CD3 bispecific protein, in adults with Previously treated AML or NSCLC.

K. Freise | E. Saâda-Bouzid | M. Moskovitz | R. Leibman | P. Peterlin | Junichiro Yuda | T. Shimizu | W. Henner | A. Pigneux | Mahipal Sinnollareddy | Diana Chen | Abraham Avigdor